Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer.

MLA

Nakao, Keiko, et al. “Population Pharmacokinetics of Afatinib and Exposure-Safety Relationships in Japanese Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer.” Scientific Reports, vol. 9, no. 1, Dec. 2019, p. 18202. EBSCOhost, https://doi.org/10.1038/s41598-019-54804-9.

APA

Nakao, K., Kobuchi, S., Marutani, S., Iwazaki, A., Tamiya, A., Isa, S., Okishio, K., Kanazu, M., Tamiya, M., Hirashima, T., Imai, K., Sakaeda, T., & Atagi, S. (2019). Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer. Scientific Reports, 9(1), 18202. https://doi.org/10.1038/s41598-019-54804-9

Chicago

Nakao, Keiko, Shinji Kobuchi, Shuhei Marutani, Ayano Iwazaki, Akihiro Tamiya, Shunichi Isa, Kyoichi Okishio, et al. 2019. “Population Pharmacokinetics of Afatinib and Exposure-Safety Relationships in Japanese Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer.” Scientific Reports 9 (1): 18202. doi:10.1038/s41598-019-54804-9.